Altogether, this data could explain the decreased CSF Nogo-A concentrations in the current cohort of patients with brain tumour (astrocytic plus meningeal) compared to non-tumoural individuals, and moreover strengthen the hypothesis that decreased CSF Nogo-A could be considered a marker for these tumours. This evidence concerns the gene RTN4 and neoplasm.